Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

8 Sept 2017

Abstract excerpt

Systematic development of combination chemotherapies has significantly improved the prognosis of acute lymphoblastic leukemia (ALL). Patients with T-cell ALL (T-ALL) still have less favorable outcomes, and the prognosis of relapsed T-ALL is dismal. 1 In order to find novel targeted therapies for T-ALL, we retrieved the gene expression profiles of 4430 leukemia samples from the Gene Expression Omnibus (GEO) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28885610
DOI: 10.1038/bcj.2017.87

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALLPMID 28885610Read ↗

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemiaSemantic proximity Read ↗

Zebrafish screen identifies novel compound with selective toxicity against leukemiaSemantic proximity Read ↗

Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature.Semantic proximity Read ↗

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.Semantic proximity Read ↗

HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathwaySemantic proximity Read ↗

Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia.Semantic proximity Read ↗

Dasatinib: a new step in molecular target therapySemantic proximity Read ↗

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.Semantic proximity Read ↗

DasatinibSemantic proximity Read ↗

Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.Semantic proximity Read ↗

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy InhibitionSemantic proximity Read ↗

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.